Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 8, 2014, Pages 1016-1024

  Balato, A ^a   Schiattarella, M ^a   Di Caprio, R ^a   Lembo, S ^a   Mattii, M ^a   Balato, N ^a   Ayala, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; CYTOKINE; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ADULT; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; METABOLISM; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH17 CELL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-17; PSORIASIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TH17 CELLS;

EID: 84905826838     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12240     Document Type: Article

References (25)

1. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
2. Blauvelt A,. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF- β1. Expert Rev Dermatol 2007; 2: 69-78.
3. Robinson DS, O'Garra A,. Further checkpoints in Th1 development. Immunity 2002; 16: 755-758. (Pubitemid 34786474)
4. Manel N, Unutmaz D, Littman DR,. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9: 641-649. (Pubitemid 351714729)
5. Vanden ES, Goriely S, De Wit D, et al,. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol 2005; 35: 469-475. (Pubitemid 40331324)
6. Annunziato F, Cosmi L, Santarlasci V, et al,. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204: 1849-1861. (Pubitemid 47240944)
7. Zheng Y, Danilenko DM, Valdez P, et al,. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-651. (Pubitemid 46232884)
8. Li J, Li D, Tan Z,. The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris. J Huazhong Univ Sci Technol Med Sci 2004; 24: 294-296. (Pubitemid 41559639)
9. Eyerich S, Eyerich K, Cavani A, et al,. IL-17 and IL-22: siblings, not twins. Trends Immunol 2010; 9: 54-61.
10. Liang SC, Tan XY, Luxenberg DP, et al,. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279. (Pubitemid 44498362)
11. Wolk K, Witte E, Wallace E, et al,. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309-1323.
12. Scott DL, Kingsley GH,. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704-712.
13. Atzeni F, Turiel M, Capsoni F, et al,. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005; 1051: 559-569.
14. Furst DE, Wallis R, Broder M, et al,. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006; 36: 159-167. (Pubitemid 44691882)
15. Lügering A, Schmidt M, Lügering N, et al,. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase dependent pathway. Gastroenterology 2001; 121: 1145-1157. (Pubitemid 33022095)
16. Shen C, Assche GV, Colpaert S, et al,. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-258. (Pubitemid 40278362)
17. Malaviya R, Sun Y, Tan JK,. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2006; 55: 590-597. (Pubitemid 44436644)
18. Wang F, Smith N, Maier L, et al,. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. Br J Dermatol 2012; 167: 92-102.
19. Zaba LC, Cardinale I, Gilleaudeau P, et al,. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-3194.
20. Soegaard-Madsen L, Johansen C, Vinter H, et al,. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy. Br J Dermatol 2010; 163: 1194-1204.
21. Kagami S, Rizzo HL, Lee JJ, et al,. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 5: 1373-1383.
22. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115. (Pubitemid 350298146)
23. Gordon K, Papp K, Poulin Y, et al,. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-251.
24. Tracey D, Klareskog L, Sasso EH, et al,. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279.
25. Harper EG, Guo C, Rizzo H, et al,. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129: 2175-2183.